

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

ELECTIONS AS TO MEANS OF RECEIPT AND LANGUAGE OF CORPORATE COMMUNICATIONS

The Company is making arrangements for the Shareholders to elect to receive the Corporate Communications (i) in electronic form on the Company's website at www.3healthcare.com (where they will continue to be published in both Chinese and English) or in printed form and (ii) if the Shareholders elect to receive the Corporate Communications in printed form, to elect to receive them in the Chinese language, in the English language or in both languages. The purposes of these arrangements are for increasing efficiency, saving costs and protecting the environment.

PROPOSED ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules and articles of association of the Company, the following arrangements will be made by the Company:

1. The Company will send a letter to its Shareholders on May 15, 2015 (the “**First Letter**”) together with a reply form with a mailing label attached for posting within Hong Kong (the “**Reply Form**”). The First Letter and the Reply Form will be in Chinese and English. The Reply Form will enable the Shareholders to elect to receive the Company's future Corporate Communications: (i) by electronic means on the Company's website at www.3healthcare.com or in printed form; or (ii) if they elect to receive the Corporate Communications in printed form, to elect to receive them in the English language only, in the Chinese language only or in both languages. The Corporate Communications will continue to be published on the Company's website in both languages.

The First Letter explains that, if the Company does not receive from a Shareholder a duly completed and signed Reply Form (or a response from a Shareholder indicating that the Shareholder objects to receiving the Corporate Communications in electronic form on the Company's website) on or before June 15, 2015, the Shareholder will be deemed, until the Shareholder informs the Company otherwise by reasonable notice in writing at the offices of the H Share Registrar, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or by email to shhaohaibiotech.ecom@computershare.com.hk, to have elected to receive all future Corporate Communications in electronic form on the Company's website instead of receiving them in printed form.

2. If a Shareholder has elected in a Reply Form to receive the Corporate Communications in printed form, the Company will send the Corporate Communications to the Shareholder in the language or languages selected by the Shareholder unless and until the Shareholder notifies the H Share Registrar in writing (at the above address) or by email to shhaohaibiotech.ecom@computershare.com.hk that the Shareholder wishes to receive the Corporate Communications in a different language (or, as the case may be, in both languages) or by electronic means on the Company's website.
3. If a Shareholder has elected in a Reply Form to receive the Corporate Communications by electronic means on the Company's website, the Company will notify the Shareholder by post when each Corporate Communication is published on the Company's website. This notification letter will be sent to the address of the Shareholder which appears in the Company's register of members maintained by the H Share Registrar.
4. When each Corporate Communication is sent by the Company in printed form to a Shareholder in accordance with the arrangements described above, a notification letter (the "**Notification Letter**") and a request form (the "**Request Form**") with postage prepaid (applicable for posting within Hong Kong only) will be attached to the relevant Corporate Communications, indicating that the Corporate Communications in a different language will be available upon request. The Notification Letter and Request Form will be in both Chinese and English. By completing and returning the Request Form to the Company through the H Share Registrar or by email to shhaohaibiotech.ecom@computershare.com.hk at any time, the Shareholder may elect to receive the Corporate Communications in a different language.

5. The Shareholders may also at any time by reasonable notice in writing (not less than 7 days) to the Company (sent to the Company's H Share Registrar at the above address or by email to shhaohaibiotech.ecom@computershare.com.hk) elect (i) to receive future Corporate Communications in printed form instead of in electronic form on the Company's website (or in electronic form on the Company's website instead of in printed form) or (ii) to change the language in which they receive the Corporate Communications in printed form. If any Shareholder who has elected (or is deemed to have elected) to receive the Corporate Communications in electronic form on the Company's website for any reason has difficulty in obtaining access to the Corporate Communications on the Company's website, the Company will upon request by the Shareholder send the Corporate Communications to the Shareholder in printed form free of charge.
6. All Corporate Communications will be available on the Company's website at www.3healthcare.com and the Stock Exchange's website at www.hkexnews.hk in both English and Chinese and in accessible format.
7. The Company is providing a hotline service (Tel: (852) 2862 8688) available during business hours (9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays) to enable Shareholders to make enquiries about the arrangements described above.
8. The First Letter and the Notification Letter will indicate that the Corporate Communications will be available on the Company's website in both English and Chinese and that the hotline service is being provided as described above.

DEFINITIONS

In this announcement, the following expressions shall have the meanings set out below unless the context requires otherwise:

"Board"	The board of directors of the Company;
"Company"	Shanghai Haohai Biological Technology Co., Ltd.* (上海昊海生物科技股份有限公司) (Stock Code: 6826);

“Corporate Communications”	any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities as defined in Rule 1.01 of the Listing Rules, including but not limited to the directors’ report, annual accounts together with a copy of the auditor’s report (and, where applicable, the summary financial report), the interim report (and where applicable, the summary interim report), notices of meetings, listing documents, circulars, proxy forms and reply slips;
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi and are unlisted Shares which are not currently listed in any stock exchange;
“Hong Kong”	The Hong Kong Special Administrative Region of the PRC;
“H Share(s)”	overseas-listed foreign share(s) with a nominal value of RMB1.00 each in the share capital of the Company which are listed on the Main Board of the Stock Exchange and are traded in Hong Kong dollars;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited;
“H Share Registrar”	Computershare Hong Kong Investor Services Limited, 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong;
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange;
“PRC”	The People’s Republic of China;
“RMB”	Renminbi, the lawful currency of the PRC;

“Share(s)” share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising the Domestic Shares and H Shares;

“Shareholder(s)” Holder(s) of the Share(s) of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, May 15, 2015

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Ling Xihua, Mr. Huang Ping and Ms. Chen Yiyi; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.

** For identification purpose only*